Zobrazeno 1 - 10
of 42
pro vyhledávání: '"U, Machein"'
Autor:
Thomas Bardin, Alexander So, Karine Lheritier, Mark Bloch, Rieke Alten, Naomi Schlesinger, Guido Junge, U. Machein
Publikováno v:
Annals of the Rheumatic Diseases. 74:544.1-544
Background Efficacy and safety of canakinumab (CAN) in frequently flaring difficult-to-treat gouty arthritis (GA) patients (pts) in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective has been published previously. Here, w
Autor:
A. Kivitz, Guido Junge, Jacques P. Brown, P. Sunkureddi, E. Toth, Karine Lheritier, U. Machein, R. Möricke
Publikováno v:
Annals of the Rheumatic Diseases. 74:1209.4-1210
Background Gouty arthritis (GA) patients who experience frequent flares and have comorbidities have limited treatment options and need effective alternative treatments. Canakinumab (CAN), a selective, human, anti-interleukin-1β monoclonal antibody,
Autor:
U. Machein, Rieke Alten, Naomi Schlesinger, Karine Lheritier, Mark Bloch, Schumacher Hr, Dominik Richard, Thomas Bardin, Alexander So
Publikováno v:
Annals of the Rheumatic Diseases. 73:785.2-785
Background There is a medical need for effective alternate treatments for acute gouty arthritis (GA) patients (pts) with frequent GA attacks in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective. 1 Canakinumab (CAN), a se
Autor:
Pierre Quartier, I Kone-Paut, Luca Cantarini, Steven J. Spalding, Andrew Zeft, Sinisa Savic, Anna Simon, Rolando Cimaz, U. Machein, Ahmet Gül, Avi Livneh, Véronique Hentgen, Ivan Foeldvari, Helen J. Lachmann, Tilmann Kallinich, J. B. Kuemmerle-Deschner, S Ozen, J Frenkel, Philip J. Hashkes
Publikováno v:
Annals of the Rheumatic Diseases. 73:106.1-106
Background Due to low incidence rates, treatment data and guidelines in hereditary periodic fevers are limited. To complement published data from the autoinflammatory diseases PRINTO/Eurofever registry, an international noninterventional study of col
Publikováno v:
Transplantation proceedings. 33(7-8)
Publikováno v:
Journal of neurochemistry. 73(5)
Interleukin-6 (IL-6) is involved in the pathophysiology of various diseases of the CNS. Because the molecular mechanism of action of this cytokine in human neurons is not well understood, we were interested in characterizing and defining a model syst
Autor:
Annette Damert, Georg Breier, Volker Rönicke, W. Risau, M R Machein, Karl H. Plate, J. Kullmer, U Machein, M Krieg
Publikováno v:
ResearcherID
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is a mitogen and chemotactic factor for endothelial cells in vitro and an angiogenesis and vascular permeability factor in vivo. Due to its properties, VEGF is a candidate for
Autor:
U, Machein, W, Conca
Publikováno v:
Advances in experimental medicine and biology. 421
Matrix metalloproteinases (MMP) are a family of structurally related endopeptidases that resorb macromolecules of the extracellular matrix (ECM). They are involved in normal tissue remodeling and wound repair as well as in pathological processes such
Publikováno v:
Fortschritte der Medizin. 113(3)
In 59 healthy subjects of different age groups with no signs of inflammatory processes, the basal II-6 levels were measured. The II-6 concentrations were significantly higher in the oldest group (66-90 years) than in the two other age groups (24-40,
Publikováno v:
Archives of virology. Supplementum. 4
We have found previously that hybrid 22-nm HBsAg particles can be created by insertion of short antigenic sequences into the HBV major envelope protein. We have now performed a detailed deletion mutagenesis of the S gene of HBV encoding HBsAg. Deleti